HROW
Harrow, Inc. Common Stock
stockNASDAQ
harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 31.60 | 2026-09-28 | -3.58% | 0.955 |
| 1M | 38.54 | 2026-09-04 | -20.94% | 0.494 |
| 3M | 44.93 | 2026-07-06 | -32.18% | 0.289 |
| 6M | 35.13 | 2026-04-06 | -13.27% | 0.692 |
| 1Y | 45.43 | 2025-10-03 | -32.93% | 1.390 |
| 2Y | 50.37 | 2024-10-04 | -39.51% | — |
| 5Y | 8.87 | 2021-10-04 | +243.52% | 1.050 |
Harrow, Inc. Common Stock (NASDAQ:HROW) stock price today is $30.47, and today's volume is 566,383. HROW is down 0.457% today. The 30 day average volume is 538,190. HROW market cap is $1.14B with 37.49M shares outstanding.